Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Triple negative breast cancer (TNBC) is a heterogeneous group of aggressive carcinomas with poor prognosis and significant genetic variability.
• Activating mutations in phosphoinositide 3-kinase catalytic subunit alpha (PIK3CA) are potential therapeutic targets in breast cancer, but their role in TNBC subtypes is not well understood.

Purpose of the Study:

• To investigate the clinical impact and prognostic value of PIK3CA protein expression in different subtypes of triple negative breast cancer.
• To correlate PIK3CA expression with patient characteristics, imaging features, and survival outcomes in TNBC.

Main Methods:

• Immunohistochemical analysis of PIK3CA protein expression in 119 TNBC samples, with semi-quantitative scoring (negative, weak, strong).
• Categorization of TNBC into four subtypes: basal-like, mesenchymal-like, luminal androgen receptor (LAR), and immunomodulatory.
• Correlation of PIK3CA expression scores with clinical data, imaging features, and TNBC subtypes.

Main Results:

• No significant differences in clinical aspects or imaging features were observed between TNBC with and without PIK3CA expression.
• PIK3CA expression was generally higher in the Luminal Androgen Receptor (LAR) subtype of TNBC.
• TNBC cases with PIK3CA protein expression demonstrated significantly better disease-free survival and overall survival, independent of TNBC subtype.

Conclusions:

• PIK3CA protein expression in triple negative breast cancer is associated with a better patient outcome, irrespective of TNBC subtype.
• PIK3CA expression does not appear to be linked to specific clinical or diagnostic features within TNBC.
• Further research, including molecular studies and meta-analyses, is needed to fully elucidate the prognostic and predictive significance of PIK3CA protein expression in TNBC.